マブチ ミユキ
馬渕 美雪 所属 兵庫医科大学 薬学部 医療薬学科 職種 助教 |
|
言語種別 | 日本語 |
発行・発表の年月 | 2004/06 |
形態種別 | 学術雑誌 |
査読 | 査読あり |
標題 | Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. |
執筆形態 | 共著 |
掲載誌名 | European journal of pharmacology |
掲載区分 | 国外 |
巻・号・頁 | 494(2-3),273-81頁 |
著者・共著者 | Minoura Hideaki, Takeshita Shigeru, Ita Makoto, Hirosumi Jiro, Mabuchi Miyuki, Kawamura Ikuo, Nakajima Satoko, Nakayama Osamu, Kayakiri Hiroshi, Oku Teruo, Ohkubo-Suzuki Akiko, Fukagawa Masao, Kojo Hitoshi, Hanioka Kenichi, Yamasaki Noritsugu, Imoto Takafumi, Kobayashi Yoshinori, Mutoh Seitaro |
概要 | We evaluated antidiabetic effects of FK614, a benzimidazole derivative without a thiazolidinedione structure, which was obtained using db/db mice. In db/db mice, the potency of FK614 for hypoglycemic effect was comparable to that of rosiglitazone and approximately 15-fold greater than that of pioglitazone. FK614 also showed a potent attenuating effect on hypertriglyceridemia in db/db mice, as well as rosiglitazone and pioglitazone. In ob/ob mice , ED(50) values of FK614 and pioglitazone for hypoinsulinemic effect were 1.3 and 11.8 mg/kg, respectively. FK614 also improved the impaired glucose tolerance in ob/ob mice. FK614 was found to activate PPAR gamma-mediated transcriptional activity in the reporter gene assay as well as thiazolidinedione derivatives, although its maximum effect was less than that of thiazolidinedione derivatives. |
DOI | 10.1016/j.ejphar.2004.04.038 |
ISSN | 0014-2999 |
PMID | 15212984 |